GlassScriptPhysician profile
Adam L Moskowitz
NPI 1679652036
$3,802.03
in general payments reported to CMS, 2019-2025
8 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $96.60 · 2021: $117 · 2022: $433 · 2023: $376 · 2024: $1,380 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,078.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $640.73 | 2019-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $500.00 | 2024-2025 | Voquezna |
| Pfizer INC. | $375.00 | 2024-2025 | |
| Gilead Sciences, INC. | $115.98 | 2019 | |
| Janssen Scientific Affairs, LLC | $40.00 | 2019 | |
| Exact Sciences Corporation | $28.48 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $23.66 | 2024 | Lagevrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Moskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.